Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®
Rigel Pharmaceuticals, Inc. (RIGL)
Last rigel pharmaceuticals, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rigel.com
Company Research
Source: GlobeNewswire
ST. LOUIS, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces an expanded arrangement with Rigel Pharmaceuticals, Inc, effective October 14, 2024, to include commercial distribution of TAVALISSE® (fostamatinib). TAVALISSE is an oral medicine that can help patients manage chronic immune thrombocytopenia (ITP) by protecting their platelets from destruction. “Under this expanded agreement, Optime Care will now manage commercial distribution for three Rigel products: TAVALISSE, GAVRETO® (pralsetinib) and Rezlidhia® (olutasidenib),” says Stephanie Wasilewski, PharmD, general manager, Optime Care. “This new phase of our collaboration reflects Rigel Pharmaceuticals’ ongoing confidence in Optime Care’s ability to support highly specialized patient populations while optimizing patient outcomes. Our patient access and HUB services, including patient assistance programs (PAP), co-pay assistance and reimbursem
Show less
Read more
Impact Snapshot
Event Time:
RIGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RIGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RIGL alerts
High impacting Rigel Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RIGL
News
- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at Citigroup Inc. from $40.00 to $49.00. They now have a "buy" rating on the stock.MarketBeat
- Rigel to Present at the Jefferies London Healthcare ConferencePR Newswire
- Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... [Yahoo! Finance]Yahoo! Finance
- Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Rigel Reports Third Quarter 2024 Financial Results and Provides Business UpdatePR Newswire
RIGL
Earnings
- 11/7/24 - Beat
RIGL
Sec Filings
- 11/8/24 - Form SC
- 11/7/24 - Form 8-K
- 11/7/24 - Form 10-Q
- RIGL's page on the SEC website